Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.
2.

Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease.

Güth U, Vetter M, Huang DJ, Heinzelmann-Schwarz V.

Ann Oncol. 2013 Feb;24(2):555-7. doi: 10.1093/annonc/mds637. No abstract available.

PMID:
23341481
3.

Baseline staging tests in primary breast cancer: a practice guideline.

Myers RE, Johnston M, Pritchard K, Levine M, Oliver T; Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative.

CMAJ. 2001 May 15;164(10):1439-44.

4.

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31.

PMID:
21452022
5.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v8-30. doi: 10.1093/annonc/mdv298. No abstract available.

PMID:
26314782
6.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Aebi S, Davidson T, Gruber G, Cardoso F; ESMO Guidelines Working Group.

Ann Oncol. 2011 Sep;22 Suppl 6:vi12-24. doi: 10.1093/annonc/mdr371. No abstract available.

PMID:
21908498
7.

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

ESMO Guidelines Working Group, Pestalozzi B.

Ann Oncol. 2007 Apr;18 Suppl 2:ii5-8. No abstract available. Erratum in: Ann Oncol. 2008 May;19(5):1027-9.

PMID:
17491045
8.

18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.

Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast Cancer Res Treat. 2012 Jan;131(1):117-26. doi: 10.1007/s10549-011-1767-9. Epub 2011 Sep 21.

PMID:
21935602
9.

[Whole-body MRI in preoperative diagnostics of breast cancer--a comparison with [corrected] staging methods according to the S 3 guidelines].

Hausmann D, Kern C, Schröder MT, Sütterlin M, Schönberg SO, Neff KW, Dinter DJ.

Rofo. 2011 Dec;183(12):1130-7. doi: 10.1055/s-0031-1281723. Epub 2011 Nov 8. German. Erratum in: Rofo. 2011 Dec;183(12):e1.

PMID:
22068844
10.

Recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

ESMO Guidelines Working Group, Kalaja VV.

Ann Oncol. 2007 Apr;18 Suppl 2:ii9-11. No abstract available. Erratum in: Ann Oncol. 2008 May;19(5):1027-9.

PMID:
17491064
11.

Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.

St Romain P, Madan R, Tawfik OW, Damjanov I, Fan F.

Hum Pathol. 2012 Mar;43(3):398-404. doi: 10.1016/j.humpath.2011.05.009. Epub 2011 Aug 12.

PMID:
21840040
12.

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Pestalozzi B, Castiglione M; ESMO Guidelines Working Group.

Ann Oncol. 2008 May;19 Suppl 2:ii7-10. doi: 10.1093/annonc/mdn071. No abstract available.

PMID:
18456775
13.

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E; ESMO Guidelines Working Group.

Ann Oncol. 2011 Sep;22 Suppl 6:vi25-30. doi: 10.1093/annonc/mdr372. No abstract available.

PMID:
21908499
14.

Incidence and kinetics of distant metastases in patients with operable breast cancer.

Kryj M, Maciejewski B, Withers HR, Taylor JM.

Neoplasma. 1997;44(1):3-11.

PMID:
9201274
15.

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, Fujii K, Nakano S, Fukutomi T, Hara K, Ichihara S, Lin Y, Kikuchi S.

J Cancer Res Clin Oncol. 2010 Jun;136(6):939-44. doi: 10.1007/s00432-009-0736-8. Epub 2009 Nov 28.

PMID:
19946706
16.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
17.

Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Kataja V, Castiglione M; ESMO Guidelines Working Group.

Ann Oncol. 2008 May;19 Suppl 2:ii11-3. doi: 10.1093/annonc/mdn072. No abstract available.

PMID:
18456744
18.

Recommendation to revise the AJCC/UICC breast cancer staging system for inclusion of proven prognostic factors: ER/PR receptor status and HER2 neu.

Murthy V, Chamberlain RS.

Clin Breast Cancer. 2011 Oct;11(5):346-7. doi: 10.1016/j.clbc.2011.05.003. Epub 2011 Aug 5. No abstract available.

PMID:
21820971
19.

[Infiltrating lobular breast cancer: histological and immunohistochemical characteristics].

Vishnevskaia IaV, Ermilova VD, Savelov NA, Nechushkin MI, Trigolosov AV, Petrovskiĭ AV, Chemeris GIu, Zakharova TI.

Arkh Patol. 2005 Jul-Aug;67(4):17-21. Russian.

PMID:
16209292
20.

The influence of young age on outcome in early stage breast cancer.

Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S, Glick JH.

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33.

PMID:
8083119

Supplemental Content

Support Center